Organizational scope and investment: evidence from the drug development strategies and performance of biopharmaceutical firms
Gespeichert in:
| Beteiligte Personen: | , |
|---|---|
| Format: | Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
Cambridge, Mass.
National Bureau of Economic Research
2004
|
| Schriftenreihe: | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series
10933 |
| Schlagwörter: | |
| Links: | http://papers.nber.org/papers/w10933.pdf |
| Umfang: | 46 S. |
Internformat
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV023591175 | ||
| 003 | DE-604 | ||
| 005 | 20100205 | ||
| 007 | t| | ||
| 008 | 050106s2004 xxu |||| 00||| eng d | ||
| 035 | |a (OCoLC)57350178 | ||
| 035 | |a (DE-599)BVBBV023591175 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c XD-US | ||
| 049 | |a DE-521 |a DE-19 | ||
| 050 | 0 | |a HB1 | |
| 100 | 1 | |a Guedj, Ilan |d 1974- |e Verfasser |0 (DE-588)129717762 |4 aut | |
| 245 | 1 | 0 | |a Organizational scope and investment |b evidence from the drug development strategies and performance of biopharmaceutical firms |c Ilan Guedj ; David Scharfstein |
| 264 | 1 | |a Cambridge, Mass. |b National Bureau of Economic Research |c 2004 | |
| 300 | |a 46 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 10933 | |
| 650 | 4 | |a Drug development |x Economic aspects | |
| 650 | 4 | |a Pharmaceutical biotechnology industry | |
| 650 | 4 | |a Research |x Economic aspects | |
| 700 | 1 | |a Scharfstein, David |e Verfasser |0 (DE-588)124151892 |4 aut | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |
| 830 | 0 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 10933 |w (DE-604)BV002801238 |9 10933 | |
| 856 | 4 | 1 | |u http://papers.nber.org/papers/w10933.pdf |z kostenfrei |3 Volltext |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-016906505 | |
Datensatz im Suchindex
| _version_ | 1818965831531364352 |
|---|---|
| any_adam_object | |
| author | Guedj, Ilan 1974- Scharfstein, David |
| author_GND | (DE-588)129717762 (DE-588)124151892 |
| author_facet | Guedj, Ilan 1974- Scharfstein, David |
| author_role | aut aut |
| author_sort | Guedj, Ilan 1974- |
| author_variant | i g ig d s ds |
| building | Verbundindex |
| bvnumber | BV023591175 |
| callnumber-first | H - Social Science |
| callnumber-label | HB1 |
| callnumber-raw | HB1 |
| callnumber-search | HB1 |
| callnumber-sort | HB 11 |
| callnumber-subject | HB - Economic Theory and Demography |
| ctrlnum | (OCoLC)57350178 (DE-599)BVBBV023591175 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01437nam a2200361zcb4500</leader><controlfield tag="001">BV023591175</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20100205 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">050106s2004 xxu |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)57350178</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023591175</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-521</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB1</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guedj, Ilan</subfield><subfield code="d">1974-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)129717762</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Organizational scope and investment</subfield><subfield code="b">evidence from the drug development strategies and performance of biopharmaceutical firms</subfield><subfield code="c">Ilan Guedj ; David Scharfstein</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, Mass.</subfield><subfield code="b">National Bureau of Economic Research</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">46 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">10933</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="x">Economic aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical biotechnology industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Research</subfield><subfield code="x">Economic aspects</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scharfstein, David</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)124151892</subfield><subfield code="4">aut</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">10933</subfield><subfield code="w">(DE-604)BV002801238</subfield><subfield code="9">10933</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://papers.nber.org/papers/w10933.pdf</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016906505</subfield></datafield></record></collection> |
| id | DE-604.BV023591175 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T13:23:15Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016906505 |
| oclc_num | 57350178 |
| open_access_boolean | 1 |
| owner | DE-521 DE-19 DE-BY-UBM |
| owner_facet | DE-521 DE-19 DE-BY-UBM |
| physical | 46 S. |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | National Bureau of Economic Research |
| record_format | marc |
| series | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| series2 | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| spelling | Guedj, Ilan 1974- Verfasser (DE-588)129717762 aut Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms Ilan Guedj ; David Scharfstein Cambridge, Mass. National Bureau of Economic Research 2004 46 S. txt rdacontent n rdamedia nc rdacarrier National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 10933 Drug development Economic aspects Pharmaceutical biotechnology industry Research Economic aspects Scharfstein, David Verfasser (DE-588)124151892 aut Erscheint auch als Online-Ausgabe National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 10933 (DE-604)BV002801238 10933 http://papers.nber.org/papers/w10933.pdf kostenfrei Volltext |
| spellingShingle | Guedj, Ilan 1974- Scharfstein, David Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series Drug development Economic aspects Pharmaceutical biotechnology industry Research Economic aspects |
| title | Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms |
| title_auth | Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms |
| title_exact_search | Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms |
| title_full | Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms Ilan Guedj ; David Scharfstein |
| title_fullStr | Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms Ilan Guedj ; David Scharfstein |
| title_full_unstemmed | Organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms Ilan Guedj ; David Scharfstein |
| title_short | Organizational scope and investment |
| title_sort | organizational scope and investment evidence from the drug development strategies and performance of biopharmaceutical firms |
| title_sub | evidence from the drug development strategies and performance of biopharmaceutical firms |
| topic | Drug development Economic aspects Pharmaceutical biotechnology industry Research Economic aspects |
| topic_facet | Drug development Economic aspects Pharmaceutical biotechnology industry Research Economic aspects |
| url | http://papers.nber.org/papers/w10933.pdf |
| volume_link | (DE-604)BV002801238 |
| work_keys_str_mv | AT guedjilan organizationalscopeandinvestmentevidencefromthedrugdevelopmentstrategiesandperformanceofbiopharmaceuticalfirms AT scharfsteindavid organizationalscopeandinvestmentevidencefromthedrugdevelopmentstrategiesandperformanceofbiopharmaceuticalfirms |